手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
7条
与
Progression-Free Survival
有关的结果
Does Time to Adjuvant Chemotherapy after Radical Cystectomy Affect Survival in Muscle Invasive Bladder Cancer? A Systematic Review
2022 年 发布于
Clin Genitourin Cancer
13 卷 第 2 期
Kronstedt S.
Doppalapudi S. K.
Boyle J.
Chua K.
Jang T. L.
Cacciamani G. E.
Ghodoussipour S.
Humans
Immunotherapy
Inflammation
Prognosis
Progression-Free Survival
*Urinary Bladder Neoplasms
文献简介
原文链接
吉西他滨较丝裂霉素治疗 TURBT 后非肌层浸润性膀胱癌的复发率低、毒副作用小 : 基于随机对照试验的荟萃分析
2021 年 发布于
PeerJ
60 卷 第 5 期
彭磊
蒙春杨
李金泽
李云祥
李进铭
赵攀
韦堂墙
伍季
Adult
Aged
Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
B7-H1 Antigen/antagonists & inhibitors
Carcinoma/*drug therapy/immunology/mortality/pathology
Clinical Decision-Making
Female
Humans
Immune Checkpoint Inhibitors/adverse effects/*therapeutic use
Male
Middle Aged
Patient Selection
Progression-Free Survival
Time Factors
Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology
Urothelium/*drug effects/immunology/pathology
Immune-checkpoint inhibitor
Meta-analysis
Programmed death-ligand 1
Urothelial carcinoma
interests/personal relationships which may be considered as potential competing
interests: The authors certify that all conflicts of interest
including specific
financial interests and relationships and affiliations relevant to the subject
matter or materials
discussed in the article are listed as follows: Shahrokh
Shariat owns or co-owns the following patents: methods to determine prognosis
after therapy for prostate cancer. Granted 2002-09-06. Methods to determine
prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic
methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas:
urinary marker for the detection of bladder transitional cell carcinoma. Granted
2010-07-20. He has a consulting or advisory role for the following: Astellas
Astra Zeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Jansen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Roche
Sanochemia
Sanofi
Takeda
Urogen and Wolff. All
remaining authors have declared no conflicts of interest.
文献简介
原文链接
Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis COMMENT
2021 年 发布于
Indian J Urol
206 卷 第 6 期
Greco F.
Administration
Intravesical
Antineoplastic Agents/*administration & dosage/adverse effects
Clinical Trials as Topic
Disease Progression
Humans
Neoplasm Metastasis
*Neoplasm Recurrence
Local
Network Meta-Analysis
Progression-Free Survival
Risk Assessment
Risk Factors
Time Factors
Urinary Bladder Neoplasms/*drug therapy/mortality/pathology
文献简介
原文链接
对比根治性膀胱切除术与以保留膀胱手术为主的综合治疗对肌层浸润性膀胱癌疗效的 Meta 分析
2021 年 发布于
Surg Oncol
205 卷 第 12 期
邓迪豪
Adult
Aged
Aged
80 and over
B7-H1 Antigen/genetics/*immunology
Female
Humans
Immune Checkpoint Inhibitors/*administration & dosage
*Immunotherapy
Male
Middle Aged
Programmed Cell Death 1 Receptor/genetics/*immunology
Progression-Free Survival
Randomized Controlled Trials as Topic
Treatment Outcome
Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy
efficacy
immunotherapy
meta-analysis
safety
urothelial cancer
this study.
文献简介
原文链接
Prognostic value of modified glasgow prognostic score in bladder cancer: a systematic review and meta-analysis
2020 年 发布于
Clin Genitourin Cancer
6 卷 第 3 期
Pang K.
Chen B.
Han C. H.
Carcinoma
Papillary/mortality/pathology/*therapy
Disease Progression
Humans
Neoplasm Staging
Progression-Free Survival
Risk Assessment
Risk Factors
Time Factors
Urinary Bladder Neoplasms/mortality/pathology/*therapy
Urothelium/*pathology
Bacillus Calmette-Guérin therapy
Bladder cancer
Bladder sparing
Immediate cystectomy
Micropapillary
Prognosis
Transurethral resection
Urothelial carcinoma
Variant histology
文献简介
原文链接
Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes
2020 年 发布于
Curr Opin Urol
33 卷 第 01 期
Kim D. K.
Kim J. W.
Ro J. Y.
Lee H. S.
Park J. Y.
Ahn H. K.
Lee J. Y.
Cho K. S.
*DNA Methylation
DNA
Neoplasm/*metabolism
Humans
Prognosis
Urinary Bladder Neoplasms/*diagnosis/*genetics
Biomarker
Bladder cancer
DNA methylation
Overall survival
Progression-free survival
文献简介
原文链接
经尿道激光和传统电切手术治疗非肌层浸润型膀胱肿瘤的 Meta 分析
2019 年 发布于
Gene
68 卷 第 2 期
郭雪涛
Antineoplastic Agents/*therapeutic use
Carcinoma
Transitional Cell/pathology/*therapy
Chemotherapy
Adjuvant
Cystectomy
Cystoscopy
Humans
Lymph Node Excision
Muscle
Smooth/*pathology
*Neoadjuvant Therapy
Neoplasm Invasiveness
*Organ Sparing Treatments
Progression-Free Survival
Proportional Hazards Models
*Radiotherapy
Adjuvant
Survival Rate
Urinary Bladder Neoplasms/pathology/*therapy
Bladder preserving
Cancer
Muscle invasive
Radical cystectomy
Trimodal
文献简介
原文链接